GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Cyclically Adjusted FCF per Share

EVOK (Evoke Pharma) Cyclically Adjusted FCF per Share : $-89.98 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Evoke Pharma's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.834. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-89.98 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Evoke Pharma was 16.80% per year. The lowest was 16.80% per year. And the median was 16.80% per year.

As of today (2025-05-12), Evoke Pharma's current stock price is $3.14. Evoke Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-89.98. Evoke Pharma's Cyclically Adjusted Price-to-FCF of today is .


Evoke Pharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Evoke Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Cyclically Adjusted FCF per Share Chart

Evoke Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -156.30 -140.67 -122.35 -89.98

Evoke Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -122.35 -118.62 -109.75 -97.87 -89.98

Competitive Comparison of Evoke Pharma's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoke Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

Evoke Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evoke Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.834/133.1571*133.1571
=-0.834

Current CPI (Dec. 2024) = 133.1571.

Evoke Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -71.310 99.621 -95.315
201506 -59.163 100.684 -78.245
201509 -55.644 100.392 -73.805
201512 -49.040 99.792 -65.436
201603 -53.800 100.470 -71.303
201606 -44.600 101.688 -58.402
201609 -32.676 101.861 -42.715
201612 -15.930 101.863 -20.824
201703 -17.947 102.862 -23.233
201706 -19.589 103.349 -25.239
201709 -20.561 104.136 -26.291
201712 -25.315 104.011 -32.409
201803 -26.336 105.290 -33.307
201806 -15.456 106.317 -19.358
201809 -9.664 106.507 -12.082
201812 -10.322 105.998 -12.967
201903 -15.926 107.251 -19.773
201906 -10.049 108.070 -12.382
201909 -6.304 108.329 -7.749
201912 -6.793 108.420 -8.343
202003 -9.129 108.902 -11.162
202006 -8.943 108.767 -10.948
202009 -9.951 109.815 -12.066
202012 -9.355 109.897 -11.335
202103 -13.671 111.754 -16.289
202106 -6.711 114.631 -7.796
202109 -26.071 115.734 -29.996
202112 -8.797 117.630 -9.958
202203 -7.083 121.301 -7.775
202206 -5.224 125.017 -5.564
202209 -3.946 125.227 -4.196
202212 -8.982 125.222 -9.551
202303 -5.846 127.348 -6.113
202306 -4.323 128.729 -4.472
202309 -3.735 129.860 -3.830
202312 -3.964 129.419 -4.078
202403 -3.407 131.776 -3.443
202406 -0.602 132.554 -0.605
202409 -0.585 133.029 -0.586
202412 -0.834 133.157 -0.834

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Evoke Pharma  (NAS:EVOK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Evoke Pharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evoke Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
420 Stevens Avenue, Suite 230, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Executives
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer director, officer: President and CEO C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio officer: Exec VP, Chief Bus. Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder director, 10 percent owner 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp 10 percent owner ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P 10 percent owner ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah 10 percent owner 12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson officer: Chief Medical Officer C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady director C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn director
Lvpmc, Llc 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p. 10 percent owner ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111